|
|
Navigating the Evolving Standards of Newly Diagnosed Multiple Myeloma Treatment: Exploring the Evidence on New Combination Strategies
ACTIVITY DESCRIPTION
The goal of treatment for newly diagnosed multiple myeloma (NDMM) patients is achieving the deepest possible remission, which typically involves aiming for minimal residual disease negativity. Frontline therapy for NDMM is evolving to include novel induction regimens with anti-CD38 antibodies, which have been shown to yield improved depth of response after induction. These new frontline treatments vary in induction regimen composition and use of transplant, consolidation,... |
|
|
The Pharmacist’s Role in Individualizing Therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, immune-mediated neurologic disorder that can lead to severe disability if left untreated. Early and accurate diagnosis for CIDP is challenging and usually delayed, but early initiation and maintenance of immunoglobulin-based treatment is crucial. Due to the heterogenous nature of the disease, treatment strategies need to be individualized, and pharmacists play an integral role through ongoing patient communications/education, ... |
|